Ketamine for the Treatment of Refractory Status Epilepticus

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Thomas Jefferson University
Study ID
NCT07177235
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Refractory Status Epilepticus

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ketamine — DRUG
    Timing of ketamine initiation will differ between groups (early versus late ketamine)
  • Midazolam — DRUG
    Midazolam infusion will be initiated at the same time in both groups

Study Details

This pilot feasibility study aims to examine how the timing of ketamine introduction as a third-line anti-seizure medication infusion relates to seizure cessation in patients with refractory status epilepticus (RSE).

Key Dates

Start date
Nov 30, 2025
Status verified
Sep 2025
Primary completion
Jul 31, 2027
Completion
Jul 31, 2028

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Early ketamine
    Initiation of ketamine infusion simultaneously with midazolam infusion as the third-line anesthetic treatment
  • Active Comparator: Late ketamine
    Initiation of ketamine infusion only after midazolam infusion has been started

Primary Outcome Measure

Time to seizure cessation [ Time Frame: 72 hours ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Thomas Jefferson University HospitalPhiladelphiaPennsylvania19107-

Find similar trials in Philadelphia, PA

By research site
Thomas Jefferson University Hospital· Philadelphia, PA

Related Studies